FDA Plays

[Guy]

TRLPF – bought @.67. They have a PDUFA on May 28th for
CompleoTRT , a testosterone replacement therapy.
They decided, following discussions with the FDA, to focus its CompleoTRT regulatory
submission on a three times a day and not twice a day dosing schedule.
This pushed the PDUFA date to May 28th (from February 28th).

Trimel also recently completed recruitment for the 240-patient, Tefina ambulatory Phase II study in
anorgasmia/female orgasmic disorder. Results should be out in Q214.

A few days ago they raised $10.5 million from current shareholders at market price:
http://finance.yahoo.com/news/trimel-announces-10-5-million-203753113.html

Trades in Canada as TRL.TO. 163 million OS shares.
Some of the people involved with TRL were also involved with Biovail (merged with Valeant and trades
as VRX on the NYSE).

February 2014 presentation:
http://www.trimelpharmaceuticals.com/Portals/0/IR%20-%20%20February%202014.pdf